PGR and metastatic neoplasm: In addition to low PgR expression levels, elevated BMI (≥30 vs. <30, p = 0.017), high tumor grade (3 vs. 1–2, p = 0.008), recurrent metastatic disease (p = 0.008), endocrine-resistant status (p < 0.001), presence of liver metastasis (p < 0.001), presence of non-only bone lesion (p < 0.001), and presence of brain metastasis (p < 0.001) were significantly correlated with poorer PFS in univariate analyses.